Retatrutide for Weight Loss: What the Phase 3 Data Actually Shows
Reviewed by Peptide Nerds Editorial · Updated March 2026
Retatrutide for Weight Loss: What the Phase 3 Data Actually Shows
Key takeaways:
- Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It is the first obesity drug to activate all three pathways.
- In Phase 3 trials, the 12mg dose produced an average of 28.7% body weight loss (roughly 71 lbs) over 68 weeks.
- That exceeds semaglutide (14.9%) and tirzepatide (22.5%) by a significant margin, following the single > dual > triple agonist progression.
- The glucagon receptor component drives increased energy expenditure and fat oxidation, a mechanism no currently approved weight loss medication offers.
- Retatrutide is NOT FDA-approved and is NOT available by prescription or online. It is only accessible through clinical trials right now.
- FDA approval is expected between mid-2026 and early 2027, pending regulatory review of the Phase 3 data.
Important: This article is for educational and informational purposes only. It is not medical advice. Retatrutide is an investigational compound that has not been approved by the FDA for any indication. Always consult a qualified healthcare provider before making decisions about your health. See our full medical disclaimer.
What is retatrutide?
Retatrutide (also known as LY3437943) is an investigational obesity medication developed by Eli Lilly. It is a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide.
What makes it different is the number of receptors it targets. Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). Retatrutide activates three: GLP-1, GIP, and the glucagon receptor.
That third target is the key. Glucagon receptor activation does something the other medications cannot do on their own. It increases energy expenditure and promotes direct fat oxidation, particularly in the liver.
In simple terms: semaglutide and tirzepatide primarily make you eat less. Retatrutide makes you eat less AND burn more.
How retatrutide produces weight loss
The triple agonist mechanism attacks weight from multiple angles simultaneously.
GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves blood sugar control. This is the same pathway semaglutide uses. It is responsible for the "I'm just not hungry" effect that GLP-1 medication users describe.
GIP receptor activation enhances the GLP-1 effect on appetite and may improve fat tissue metabolism. This is the second pathway tirzepatide added, which is partly why tirzepatide outperforms semaglutide.
Glucagon receptor activation is the new addition. Glucagon signals the liver to release stored energy. When activated alongside GLP-1 and GIP, it increases resting energy expenditure (your body burns more calories at baseline) and promotes fat oxidation in the liver. This is why retatrutide showed dramatic reductions in liver fat in the Phase 2 trial (PMID: 37385275).
The combination means retatrutide works on both sides of the energy equation. It reduces calorie intake (demand side) while increasing calorie burn (supply side). No currently approved obesity medication does both this effectively.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Phase 3 clinical trial results
In February 2026, Eli Lilly announced topline results from its Phase 3 program for retatrutide. The numbers exceeded what most researchers expected, even after the strong Phase 2 showing.
Here are the headline results over 68 weeks of treatment:
| Dose | Average Body Weight Loss | Average Pounds Lost |
|---|---|---|
| 9 mg | 26.4% | ~65 lbs |
| 12 mg | 28.7% | ~71 lbs |
| Placebo | ~2% | ~5 lbs |
The 12mg group lost an average of 28.7% of their total body weight. For a 250-pound person, that translates to roughly 71 pounds in just over a year.
These results build on the Phase 2 data published in the New England Journal of Medicine, which showed up to 24.2% weight loss in 48 weeks at the 12mg dose (PMID: 37385275). The longer treatment period in Phase 3 (68 weeks vs. 48 weeks) and larger participant pool confirmed that the weight loss trajectory continues well beyond what Phase 2 captured. For a full breakdown of the earlier data, see our Phase 2 results analysis.
Beyond weight loss: the osteoarthritis signal
One finding that received less attention but matters enormously: a 75.8% reduction in knee pain among participants with osteoarthritis. Excess weight is the leading modifiable risk factor for knee osteoarthritis, so this is not surprising. But the magnitude of pain reduction suggests retatrutide could become a meaningful treatment for obesity-related joint disease, not just obesity itself.
This broadens the clinical case for the drug and may influence how quickly it moves through regulatory review.
How retatrutide compares to semaglutide and tirzepatide
The progression from single to dual to triple agonist has produced a clear pattern of increasing weight loss at each step.
| Medication | Receptors | Trial Duration | Avg. Weight Loss |
|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 | 68 weeks | 14.9% |
| Tirzepatide 15mg | GLP-1 + GIP | 72 weeks | 22.5% |
| Retatrutide 12mg | GLP-1 + GIP + Glucagon | 68 weeks | 28.7% |
Each additional receptor target has added roughly 7-8 percentage points of weight loss. The glucagon component appears to be a genuine differentiator, not just incremental improvement.
For a more detailed breakdown, see our semaglutide vs. tirzepatide vs. retatrutide comparison and our tirzepatide vs. retatrutide comparison.
It is important to note these are cross-trial comparisons, not head-to-head studies. Trial populations, designs, and baseline characteristics differ. Direct comparison trials would give us more definitive answers. Still, the gap between retatrutide and existing medications is large enough that most researchers consider the advantage real.
Dosage and titration schedule
Retatrutide uses a gradual titration schedule, similar to semaglutide and tirzepatide. You do not start at the full dose. Instead, the dose increases every 4 weeks to reduce side effects.
Based on clinical trial protocols, the titration schedule looks like this:
| Weeks | Dose |
|---|---|
| 1-4 | 1 mg |
| 5-8 | 2 mg |
| 9-12 | 4 mg |
| 13-16 | 6 mg |
| 17-20 | 8 mg |
| 21+ | 9 mg or 12 mg (maintenance) |
The 9mg and 12mg maintenance doses both showed strong results. The 12mg dose produced more weight loss but also higher rates of certain side effects (discussed below). The choice between maintenance doses will likely depend on individual response and tolerability.
For the full dosage breakdown, see our dedicated retatrutide dosage page.
Side effects
The side effect profile follows a familiar pattern if you have experience with GLP-1 medications. Gastrointestinal symptoms dominate, especially during dose escalation.
Common side effects from the Phase 3 data:
| Side Effect | Approximate Incidence |
|---|---|
| Nausea | 38% |
| Diarrhea | 34% |
| Decreased appetite | Frequently reported |
| Vomiting | 15-20% |
| Constipation | 10-15% |
Most GI side effects were mild to moderate and decreased over time as participants adjusted to each dose level. This mirrors the experience with semaglutide and tirzepatide, where the first few weeks at each new dose tend to be the worst.
The dysesthesia signal
One side effect that sets retatrutide apart from existing medications: dysesthesia. This is an abnormal sensation, often described as tingling, numbness, or burning, typically in the extremities.
In Phase 3, dysesthesia was reported in approximately 8.8% of participants at 9mg and 20.9% at 12mg. This is a higher rate than seen with semaglutide or tirzepatide and appears to be linked to the glucagon receptor component.
The clinical significance of this finding is still being evaluated. For most participants, the symptoms were mild and manageable. But it will be a key point of discussion during FDA review.
For a full list of reported effects, see our retatrutide side effects page.
When can you get retatrutide?
Right now, retatrutide is only available through enrollment in active clinical trials. It is not approved by the FDA, and it is not available by prescription, at pharmacies, or through online telehealth platforms.
Anyone selling "retatrutide" online is selling a research chemical that has not been verified for purity, safety, or dosing accuracy. We strongly advise against purchasing peptides from unregulated sources for self-administration.
Based on the Phase 3 data release in February 2026, Eli Lilly is expected to file for FDA approval in 2026. If the review process follows a standard timeline, approval could come as early as mid-2026 (if granted priority review) or more likely in early 2027.
For ongoing updates, see our retatrutide FDA approval timeline tracker.
Who might benefit most from retatrutide
While we cannot make medical recommendations (that is your doctor's job), the clinical data suggests certain populations may see the greatest benefit from retatrutide if approved.
People who have not responded well to GLP-1 only medications. Some patients plateau on semaglutide or do not achieve sufficient weight loss. The additional receptor targets in retatrutide may overcome that plateau.
People with severe obesity (BMI 40+). The higher magnitude of weight loss means retatrutide may be more appropriate as a first-line option for patients who need to lose a larger percentage of their body weight.
People with obesity-related fatty liver disease. The glucagon receptor component drives significant liver fat reduction, which sets retatrutide apart from purely appetite-based medications.
People with obesity-related joint pain. The Phase 3 osteoarthritis data (75.8% knee pain reduction) suggests meaningful benefits for this population.
For a broader overview of weight loss peptides and medications, see our weight loss goals page.
Frequently asked questions
Is retatrutide better than semaglutide?
In terms of raw weight loss numbers, yes. Retatrutide produced 28.7% body weight loss compared to semaglutide's 14.9%. However, "better" depends on individual factors including side effect tolerance, availability, cost, and your doctor's recommendation. Semaglutide has years of real-world safety data that retatrutide does not yet have.
Can I buy retatrutide online?
No. Any retatrutide sold online is an unregulated research chemical. It has not been approved by the FDA and is not legally available as a prescription medication. We do not recommend purchasing research peptides for self-administration.
How much weight can you lose on retatrutide?
In Phase 3 trials, participants on the 12mg dose lost an average of 28.7% of their body weight over 68 weeks. That is approximately 71 pounds for someone starting at 250 lbs. Individual results will vary based on starting weight, dose, diet, activity level, and other factors.
Will retatrutide replace semaglutide and tirzepatide?
Probably not entirely. It will likely become another option in the toolkit. Some patients do well on semaglutide and may not need a triple agonist. Others may prefer retatrutide for its additional mechanisms. Insurance coverage, pricing, and side effect profiles will all influence prescribing patterns.
When will retatrutide be FDA-approved?
Based on current timelines, Eli Lilly is expected to submit for approval in 2026. If granted priority review, approval could come by late 2026. A more conservative estimate is early 2027. See our FDA approval timeline tracker for the latest updates.
This article was last reviewed on March 6, 2026. We update our content as new research and clinical data become available. If you found this guide helpful, explore our full library of weight loss peptide research.
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.